Mitochondrial toxicity and body shape changes during nucleos(t)ide analogues administration in patients with chronic hepatitis B
| Autor: | Salvatore Zaru, Diego F. Calvisi, Paola Bagella, Silvia Ortu, M. Melis, Giovanni Garrucciu, Giordano Madeddu, Alberto Augusto Muredda, Sergio Babudieri, Franco Bandiera, Vito Fiore, Franca Mannu |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Male
0301 basic medicine RNA Mitochondrial lcsh:Medicine Group A Gastroenterology Group B 0302 clinical medicine lcsh:Science Adiposity Multidisciplinary Lamivudine Entecavir Middle Aged Hepatitis B Mitochondria Mitochondrial toxicity Drug Therapy Combination Female 030211 gastroenterology & hepatology medicine.drug Hepatitis B virus medicine.medical_specialty Guanine Organophosphonates Antiviral Agents DNA Mitochondrial Peripheral blood mononuclear cell Article 03 medical and health sciences Hepatitis B Chronic Internal medicine Drug Resistance Viral medicine Humans Tenofovir business.industry Adenine lcsh:R medicine.disease Cross-Sectional Studies 030104 developmental biology Viral infection DNA Viral Leukocytes Mononuclear lcsh:Q business Nucleoside |
| Zdroj: | Scientific Reports, Vol 10, Iss 1, Pp 1-9 (2020) Scientific Reports |
| ISSN: | 2045-2322 |
| DOI: | 10.1038/s41598-020-58837-3 |
| Popis: | Our study purpose was to evaluate mitochondrial (mt)DNA and RNA in peripheral blood mononuclear cells (PBMCs) and body shape changes (BSC) in HBV-infected patients. mtDNA and mtRNA were measured in PBMCs. The presence of BSC was evaluated through a questionnaire and clinical evaluation. A total of 157 subjects were enrolled, of these 107 were HBV-infected patients, 54 receiving nucleoside analogues (NAs, Group A), 53 naive to antivirals (Group B) and 50 age-sex matched controls (Group C). All HBV-treated patients had negative HBV–DNA. Twenty (37,0%) received lamivudine + adefovir, 20 (37.0%) tenofovir, 2 (3.7%) lamivudine and 12 (22.2%) entecavir. Therapy median duration was 38 months (IQR 20–60) in NA-treated patients. Group A showed significantly higher mtDNA/nuclear (n) DNA ratio (p = 0.000008) compared to Group C and Group B (p = 0.002). Group B showed significantly higher mtDNA/nDNA ratio compared to Group C (p = 0.017). Group A and B had significantly lower mtRNA/nRNA ratio compared to Group C (p = 0.00003 and p = 0.00006, respectively). Tenofovir and entecavir showed less impact compared to lamivudine + adefovir. mtDNA/nDNA ratio positively (Rho = 0.34, p st generation NA. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|